Scottish National Blood Transfusion Service Overview

Overview of Scottish National Blood Transfusion Service (SNBTS)
  • Part of NHS National Services Scotland.
  • Responsible for ensuring the safety, quality, and traceability of blood and blood components.
Regulatory Framework
Key Regulations
  • UK Statutory Instrument Blood Safety Quality Regulations 2005/50 (as amended) regulates blood transfusion services in the UK.
  • 'Red Book': Guidelines for Blood Transfusion Services in the UK.
  • European Good Practice Guidelines by EDQM (European Directorate for the Quality of Medicines).
  • SaBTO: Safety of Blood, Tissue, and Organs Regulatory guidelines.
  • ISO 15189: Medical laboratories standards for quality and competence.
Blood Safety and Quality Standards
  • Purpose: Sets standards for collection, testing, processing, storage, and distribution of human blood and its components.
  • Applies to:
    • Collection and testing of blood for transfusions.
    • Processing, storage, and distribution intended for medical use.
Key Requirements
  • Suitable Facilities & Equipment: Ensuring adequate infrastructure for blood handling.
  • Trained Staff: Continuous training programs for staff involved in blood services.
  • Quality Management System (QMS): All processes validated, maintaining high-quality standards.
  • Documentation: Valid and precise records required for operations, including traceability for 30 years.
  • Recall Procedures: Must have processes in place to manage product recalls if necessary.
  • Data Protection: Compliance with GDPR and assurance of confidentiality of donor and patient data.
Blood Components
Establishment Types
  • Blood Establishment: Collects blood for transfusion or medicinal product manufacturing. Conducts donor tests, processes, and distributes blood.
  • Hospital Blood Bank: Stores and distributes blood, conducts compatibility tests for hospital uses.
Traceability
  • Defined as the ability to trace blood units from donor to patient or disposal, ensuring full accountability at all times.
    • Records maintained should include:
    • Donation Number
    • Component type
    • Date provided
    • Blood establishment name
    • Patient identity or outcomes.
Haemovigilance
  • Process for monitoring and reporting adverse reactions/events related to blood transfusions and ensuring safety throughout the transfusion chain.
  • Aims to prevent unforeseen adverse reactions and improve transfusion safety measures.
Serious Adverse Events/Serious Adverse Reactions
Definitions
  • Serious Adverse Event (SAE): Any untoward occurrence associated with blood that could impact patient safety, such as potentially fatal reactions.
  • Serious Adverse Reaction (SAR): Unintended responses in donors or patients detrimental to health.
Donor Eligibility and Health Checks
  • Extensive checks done to determine a donor’s suitability, ensuring safety for both donors and recipients.
  • Confidential health questionnaires assess risk factors and other health-related information.
Blood Testing Requirements
  • Mandatory testing for viruses and blood groups (ABO & Rh) as part of the safety protocols to ensure blood donation quality.
Labeling and Traceability Standards
  • Each blood unit must be labeled appropriately with essential information for identification and traceability.
  • Information required on labels:
    • Official component name
    • Blood group and Rh type
    • Unique donation identifier
    • Expiry date and storage conditions.
Tissue and Cell Regulations
  • Governed under similar frameworks as blood, focusing on quality safety for human tissues intended for application or transplantation.
Medicinal Products Regulations
  • Governed by the UK Human Medicines Regulation outlining requirements and standards for medicinal products derived from blood, tissues, and cells.
  • ATMP (Advanced Therapy Medicinal Products): Includes gene and somatic cell therapy medications and regulations for their development and distribution.
Clinical Trials Process
  • Clinical trials are conducted in phases assessing safety and efficacy over time, with stringent protocols for monitoring.
  • Phase Overview:
    • Preclinical: Laboratory studies for initial observations.
    • Phase 1: Safety evaluation in healthy volunteers.
    • Phase 2: Assessing safety and dosing.
    • Phase 3: Confirming effectiveness with a larger population.
    • Phase 4: Post-marketing surveillance for long-term benefits and side effects.
Compliance and Regulatory Bodies
  • Must maintain compliance with various regulatory bodies like the MHRA (Medicines and Healthcare products Regulatory Agency) and UKAS (United Kingdom Accreditation Service) for laboratory standards.
Conclusion
  • SNBTS plays a critical role in the healthcare system by ensuring the safe and effective use of blood and its components through comprehensive regulations, quality standards, and ongoing vigilance.